Seqens, a developer and producer of active pharmaceutical ingredients, pharmaceutical intermediates, and specialty ingredients, has named Pascal Villemagne as Chief Executive Officer, effective April 1, 2025.

Villemagne brings a wealth of experience to the role, having previously served as CEO of Carbogen Amcis, a company specializing in the manufacture and development of custom APIs, where he was instrumental in the transformation of the company, successfully leading structural changes and supporting the organization’s digital transformation.

Previously, Villemagne cultivated a career within the life sciences sector, holding a number of senior commercial and operational leadership positions. His experience encompasses roles such as Vice President, Contract Manufacturing, at Farmhispania, a Spanish API contract manufacturing organization, and Sales and Business Development Manager at both Inabata and Cambrex. Earlier in his career, he served as Raw Material Purchasing Manager at Sanofi.

Villemagne commented, “I am thrilled to join Seqens as its next CEO and excited to collaborate with SK Capital to drive the company’s future success. Seqens’ strong, technology-driven product portfolio has established it as a true market leader, and I am particularly drawn to the company’s commitment to these vital markets. I believe Seqens is uniquely positioned to provide exceptional value to its customers through cost-effective, sustainable solutions and best-in-class quality. The strategic investments in technology and capacity under SK Capital’s ownership have created a powerful platform for Seqens to continue exceeding customer expectations.”

Aaron Davenport, Managing Director at SK Capital, commented, “We are thrilled to welcome Pascal, who we believe is uniquely positioned to lead Seqens in its next chapter, bringing a track record of successful leadership in the pharmaceutical services industry. I would also like to thank Pierre Luzeau for his leadership and partnership with SK Capital, and I am truly excited for his next phase with the Company.”

Luzeau has served as the CEO of Seqens since 2006 and is joining the Supervisory Board as an Independent Director and Chairman of the Seqens CSR Committee. In this role, he will continue to provide insight and direction following his successful growth and development of Seqens.